{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:47:55Z","timestamp":1758991675308},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>In this study, we aimed to evaluate the efficacy and safety of intravitreal conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Three consecutive intravitreal injections of conbercept following a pro re nata protocol. The main outcomes were the changes of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity and central retinal thickness between the baseline and the 12th month.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean best-corrected visual acuity was improved from 39.39 \u00b1 24.91 letters at the baseline to 44.26 \u00b1 22.89 letters at the final follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). At the 12th month, the proportion of optimal response was 43.48% compared with 36.96% of poor response and 19.56% of nonresponse. A mean central retinal thickness of 480.94 \u00b1 178.47 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m at the baseline was significantly reduced to 366.33 \u00b1 173.52 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m at the 12th month. Patients received a median of 5.32 intravitreal injections. At the 12th month, the mean change in best-corrected visual acuity of eyes with intraretinal cystoid fluid from the baseline was markedly lower than that of eyes without intraretinal cystoid fluid. No adverse events were attributed to conbercept.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>With 12-month follow-up, conbercept was proved to be an effective and safety treatment for patients with treatment-naive neovascular age-related macular degeneration in real-life setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002152","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T19:27:48Z","timestamp":1521228468000},"page":"1353-1360","source":"Crossref","is-referenced-by-count":5,"title":["CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA"],"prefix":"10.1097","volume":"39","author":[{"given":"Xun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"},{"name":"Department of Ophthalmology, the Third People's Hospital of Chengdu, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zirong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis","volume":"117","author":"Kawasaki","year":"2010","journal-title":"Ophthalmology"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/17512433.2015.990379","article-title":"Current choice of treatments for neovascular AMD","volume":"8","author":"Lai","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R6-20230816","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","article-title":"One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration","volume":"159","author":"Arcinue","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"e70544","DOI":"10.1371\/journal.pone.0070544","article-title":"Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/17512433.2015.1075879","article-title":"Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration","volume":"8","author":"Nguyen","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/bjo.2009.175976","article-title":"Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres","volume":"95","author":"Ritter","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","article-title":"The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm Res"},{"key":"R16-20230816","first-page":"185","article-title":"Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept","volume":"21","author":"Du","year":"2015","journal-title":"Mol Vis"},{"key":"R17-20230816","first-page":"37","article-title":"Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys","volume":"14","author":"Zhang","year":"2008","journal-title":"Mol Vis"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","article-title":"Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit","volume":"97","author":"Li","year":"2012","journal-title":"Exp Eye Res"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang","year":"2011","journal-title":"Ophthalmology"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/bjophthalmol-2012-302167","article-title":"Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration","volume":"96","author":"Pushpoth","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dom.12008","article-title":"KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF","volume":"15","author":"Chen","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"R25-20230816","first-page":"459","article-title":"Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy","volume":"33","author":"Penha","year":"2013","journal-title":"Retina-J Ret Vit Dis"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/eye.2016.227","article-title":"A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration","volume":"31","author":"Schmidt-Erfurth","year":"2017","journal-title":"Eye (Lond)"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","article-title":"Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy","volume":"98","author":"Ritter","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamaophthalmol.2015.4948","article-title":"Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration","volume":"134","author":"Waldstein","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201907000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:17:13Z","timestamp":1692231433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201907000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002152","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}